The Food and Drug Administration (FDA) on Friday announced it handed down an emergency use authorization for Eli Lilly and Company’s bebtelovimab, a monoclonal antibody treatment for COVID-19. The drug is intended for the treatment of mild to moderate COVID-19, the illness caused by the CCP (Chinese Communist Party) virus in patients aged 12 and older who tested positive for COVID-19 and are “at high risk for progression to severe” disease, including hospitalization or death. It also applies to individuals for which “alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate,” according to an FDA news release. “Bebtelovimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19,” said the federal drug regulator. “Treatment with bebtelovimab has not been studied in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bebtelovimab, may be associated with …